Quercetin as Possible Supportive Therapy for Mild to Moderate Hyperuricemia

Liaquat University of Medical & Health Sciences

Status: Completed

Conditions: Hyperuricemia

Treatments: Dietary Supplement: Quercetin; Combination Product: Berberol K®

Study type: Interventional

Funder types: Other

Identifiers

NCT06591767

88_18.01.2023_QuercetinFit

Details and patient eligibility

About

Uric acid, a metabolic byproduct of purine degradation in humans, is a known risk factor for conditions such as gout and type 2 diabetes. Research has shown that supplementation with quercetin can significantly reduce plasma uric acid levels in individuals with mild hyperuricemia, potentially mitigating these associated risks.

Full description

Uric acid, a metabolic byproduct of purine degradation in humans, is a significant risk factor for the development of gout and type 2 diabetes. Supplementation with quercetin, a flavonol not naturally produced by the human body, has been shown to significantly reduce plasma uric acid levels in individuals with mild hyperuricemia. This effect is primarily achieved through the inhibition of xanthine oxidoreductase, an enzyme crucial to uric acid production.

Quercetin is the most abundant polyphenol found in fruits and vegetables and is widely used as a dietary supplement to boost the immune system and promote overall health. It is characterized by three key properties: antioxidant, anti-inflammatory, and immunomodulatory. These combined actions make quercetin a promising candidate for supporting various health conditions where oxidative stress, inflammation, and immune function play a role, including cardiovascular health, healthy aging, bone and joint health, sports and physical activity, gut health, and respiratory well-being.

The above-described properties of quercetin prompted investigators to explore its potential uricosuric therapeutic effect in two clinical studies. The first study will assess this effect in a retrospective cohort of COVID-19 patients who received quercetin as a supplemental therapy. In the second study, its potential uricosuric therapeutic effect will be assessed in a randomized controlled prospective clinical trial involving patients with mild to moderate hyperuricemia.

Enrollment: 64 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Aged between 18 and 75 years.
• Diagnosed with obesity.
• Diagnosed with hypercholesterolemia.
• With or without moderate hyperuricemia (serum uric acid ≥ 8 mg/dL).
• No restrictions on BMI, alcohol consumption, or smoking habits.

Exclusion criteria

• Current use of uric acid-lowering medications (e.g., allopurinol, febuxostat).
• Diagnosed with oncological diseases.
• Diagnosed with neurological diseases.
• Diagnosed with inflammatory bowel diseases.

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

64 participants in 3 patient groups

Quercetin group

Experimental group

Description:

In this group hyperuricemic patients (uric acid \> 8 mg/dL) received oral supplemental Quercetin, twice a day for 90 days.

Treatment:

Dietary Supplement: Quercetin

Control group 1

Active Comparator group

Description:

In this group hyperuricemic patients (uric acid \> 8 mg/dL) received oral supplemental Berberine and monacolins based supplement, twice a day for 90 days.

Treatment:

Combination Product: Berberol K®

Control group 2

Active Comparator group

Description:

In this group normouricemic patients (uric acid \< 7 mg/dL) received oral supplemental Berberine and monacolins based supplement, twice a day for 90 days.

Treatment:

Combination Product: Berberol K®